Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.89 |
| ▸ | ITGAV | P06756 | 3/20 | 0.89 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.66 |
| ▸ | ITGB7 | P26010 | 10/20 | 0.66 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316590 | 0.96 | ITGB1 (0.89) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3316443 | 0.96 | ITGB1 (0.89) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL8352229 | 0.94 | ITGB1 (1.00) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3313373 | 0.94 | ITGB1 (1.00) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3313356 | 0.94 | ITGB1 (1.00) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3316398 | 0.94 | ITGB1 (1.00) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL1028109 | 0.90 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3318272 | 0.89 | ITGB1 (0.85) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL3316690 | 0.89 | ITGB1 (0.85) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3314255 | 0.88 | ITGB1 (0.87) | ITGB1ITGAVITGA4ITGB7ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902045-B1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA SA (BE) | 2011-01-19 | — | — | EP | claimed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | claimed |
| EP-1902045-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB Pharma, S.A. (BE) | 2008-03-26 | — | — | EP | claimed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | claimed |
| WO-2006131200-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA, S.A. (BE) | 2006-12-14 | — | — | WO | claimed |
| EP-1902045-B1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA SA (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | disclosed |
| EP-1902045-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB Pharma, S.A. (BE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006131200-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA, S.A. (BE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | CYP2D6, UGT1A6, CYP3A4 | ITGB1 4685/4885ITGAV 3968/4885ITGA4 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.